The Trump administration is moving to make six experimental peptides more widely available, allowing compounding pharmacies to produce the substances as federal health officials work to ease existing restrictions.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.